Hamps Bio Ltd (544312)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Hamps Bio's revenue was ₹44.8 Cr (+43.3% year on year), and net profit ₹-5.4 Cr (against a profit a year earlier); the operating margin was -3.3%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹44.8 | +43.3% | — |
| Operating profit | ₹-1.5 | to loss | — |
| Net profit | ₹-5.4 | to loss | — |
| EPS (₹) | -6.23 | to loss | — |
| Operating margin | -3.3% | — | — |
📢 Recent Corporate Announcements
Hamps Bio Limited has submitted its Annual Report for the financial year 2025-26 under Regulation 34(1) of SEBI LODR Regulations. The report covers the company's 19th Annual General Meeting details, corporate governance, and updates on its core business verticals: Pharmaceutical Formulations and Freeze-Dried Ingredients. Additionally, the report mentions the integration of HSDL Innovative Private Limited as a wholly-owned subsidiary and its consumer brand initiatives under FzyEzy. Financed against FY26 full-year revenue of Rs 8.52 crore and a net loss of Rs 0.65 crore, the company operates manufacturing units in Ankleshwar and Surat.
- Submission of the 19th Annual Report for the financial year 2025-26
- Company operates manufacturing capabilities across Ankleshwar and Bhatpore, Surat
- Highlights the integration of HSDL Innovative Private Limited as a wholly-owned subsidiary
- Focus on expanding consumer-facing brands including FzyEzy and OxyneXt
Hamps Bio Limited has issued notice convening its 19th Annual General Meeting (AGM) on Wednesday, September 9, 2026, at 12:00 PM at the company's registered office. The meeting will consider standard annual business and discuss the FY26 (2025-26) annual report. For FY26, the company posted revenue of Rs 8.52 crore and a net loss of Rs 0.65 crore against Rs 6.67 crore revenue and Rs 0.30 crore net profit in FY25. This notice is a routine statutory corporate filing.
- 19th Annual General Meeting convened for September 9, 2026 at 12:00 PM
- Meeting to transact business outlined in the Annual Report for FY 2025-26
- Company FY26 annual revenue stood at Rs 8.52 crore with a net loss of Rs 0.65 crore
- Promoter holding remained stable at 71.99% as of March 2026
Hamps Bio Ltd has scheduled its 19th Annual General Meeting (AGM) for September 9, 2026, to approve the FY26 financial results and the re-appointment of Director Mrs. Pallavi Herrik Shah. A key proposal includes shifting the company's registered office from Ankleshwar to Surat, Gujarat, pending shareholder approval. This follows a fiscal year (FY26) where the company reported a net loss of Rs 0.65 crore on revenue of Rs 8.52 crore, a significant decline from the Rs 0.30 crore profit in FY25.
- 19th Annual General Meeting scheduled for September 9, 2026, at 12:00 noon.
- Proposed shifting of registered office from Ankleshwar to Surat, Gujarat.
- FY26 annual revenue reported at Rs 8.52 crore compared to Rs 6.67 crore in FY25.
- Company reported a net loss of Rs 0.65 crore for FY26 against a profit of Rs 0.30 crore in FY25.
- Board recommended the re-appointment of Mrs. Pallavi Herrik Shah as Director.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
